ReviewJournal of innate immunity2025
Interaction between Group 3 Innate Lymphoid Cells, Microbiota, and Intestinal Diseases: Mechanisms and Therapeutic Potential.
Review in Journal of innate immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A pro-inflammatory neutrophil subpopulation drives intestinal ischemia-reperfusion injury via the ATF4-mediated endoplasmic reticulum stress pathway.Scientific reports · 2026Article
- Plasticity and antigen presentation by group 3 innate lymphoid cells in colorectal cancer.Frontiers in immunology · 2026Review
- Restoration of peripheral ILC3s by washed microbiota transplantation improves lipid profiles in hyperlipidemia patients.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of intestinal diseases is increasing every year, placing a heavy burden on the world's health and economy. The interaction of immune, microbial, and environmental factors leading to chronic inflammation and immune dysfunction has gradually become a focus of research on the pathogenesis of intestinal diseases. Among them, type 3 innate lymphoid cells (ILC3s) have attracted much attention due to their unique features. SUMMARY: This paper has been carefully reviewed to provide a comprehensive overview of the roles of ILC3s in maintaining the homeostasis of intestinal flora. Initially, the effects of various intestinal microbiota, including bacteria, fungi, viruses, and pathogenic bacteria, on the function of ILC3s were introduced in detail. Subsequently, it summarizes how ILC3 imbalance disrupts the intestinal barrier and leads to digestive diseases, including infectious diseases, colorectal cancer, inflammatory bowel disease, and irritable bowel syndrome. KEY MESSAGES: By reviewing the role of ILC3s in maintaining the homeostasis of the intestinal flora and the current research status of ILC3s imbalance disrupting the intestinal barrier and leading to digestive tract diseases, this review provides potential immunotherapy targets for the future and offers a basis for the construction of future animal models and the conduct of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.